Targeted therapies for renal cell carcinoma: understanding their impact on survival

@article{Pal2010TargetedTF,
  title={Targeted therapies for renal cell carcinoma: understanding their impact on survival},
  author={Sumanta Kumar Pal and Robert Alan Figlin},
  journal={Targeted Oncology},
  year={2010},
  volume={5},
  pages={131-138}
}
Within the past 5 years, the United States Food and Drug Administration have approved six targeted agents for the treatment of metastatic renal cell carcinoma (mRCC). While this offers great potential to patients afflicted with this disease, oncologists are faced with the challenge of applying each agent in the appropriate clinical setting. Doing so requires an intricate understanding of the pivotal trials evaluating these agents. Herein, we have provided a detailed analysis of the study design… CONTINUE READING